Skip to content

Advertisement

Articles

Page 1 of 2

  1. Content type: Case report

    Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease ...

    Authors: Graziela Zibetti Dal Molin, Carina Meira Abrahão, Robert L. Coleman and Fernando Cotait Maluf

    Citation: Gynecologic Oncology Research and Practice 2018 5:6

    Published on:

  2. Content type: Meeting Report

    In India, cervical cancer accounts for almost 14% of all female cancer cases. Although poverty continues to cast a wide net over the Indian subcontinent, the preceding three decades have borne witness to impro...

    Authors: K. S. Tewari, A. Agarwal, A. Pathak, A. Ramesh, B. Parikh, M. Singhal, G. Saini, P. V. Sushma, N. Huilgol, S. Gundeti, S. Gupta, S. Nangia, S. Rawat, S. Alurkar, V. Goswami, B. Swarup…

    Citation: Gynecologic Oncology Research and Practice 2018 5:5

    Published on:

  3. Content type: Research

    Measuring QoL is essential to the field of gynecologic oncology but there seems to be limited standardized data regarding collecting QoL assessments throughout a patient’s cancer treatment especially in non-cl...

    Authors: D. Barnes, R. Rivera, S. Gibson, C. Craig, J. Cragun, B. Monk and D. Chase

    Citation: Gynecologic Oncology Research and Practice 2018 5:4

    Published on:

  4. Content type: Research

    The burden of HIV and cervical cancer is concentrated in sub-Saharan Africa. Women with HIV are more likely to have persistent HPV infection leading to cervical abnormalities and cancer. Cervical cancer screen...

    Authors: Nancy Innocentia Ebu

    Citation: Gynecologic Oncology Research and Practice 2018 5:3

    Published on:

  5. Content type: Research

    Gynaecological cancers may be the sentinel malignancy in women who carry a mutation in BRCA1 or 2, a mis-match repair gene causing Lynch Syndrome or other genes. Despite published guidelines for referral to a ...

    Authors: Hanoon P. Pokharel, Neville F. Hacker and Lesley Andrews

    Citation: Gynecologic Oncology Research and Practice 2018 5:2

    Published on:

  6. Content type: Review

    Combretastatin A4-phosphate (CA4P) is a vascular-disrupting agent (VDA) in clinical development for the treatment of ovarian and other cancers. In contrast to antiangiogenic agents, such as bevacizumab, which ...

    Authors: Rachel Grisham, Bonnie Ky, Krishnansu S. Tewari, David J. Chaplin and Joan Walker

    Citation: Gynecologic Oncology Research and Practice 2018 5:1

    Published on:

  7. Content type: Research

    In Ethiopia, cervical cancer is ranked as the second most common type of cancer in women and it is about 8 times more common in HIV infected women. However, data on knowledge of HIV infected women regarding ce...

    Authors: Daniel Asfaw Erku, Adeladlew Kassie Netere, Amanual Getnet Mersha, Sileshi Ayele Abebe, Abebe Basazn Mekuria and Sewunet Admasu Belachew

    Citation: Gynecologic Oncology Research and Practice 2017 4:20

    Published on:

  8. Content type: Review

    Endometrial cancer is the most common gynecologic malignancy in the United States, accounting for 6% of cancers in women. In 2017, an estimated 61,380 women were diagnosed with endometrial cancer, and approxim...

    Authors: Vicky Makker, Angela K. Green, Robert M. Wenham, David Mutch, Brittany Davidson and David Scott Miller

    Citation: Gynecologic Oncology Research and Practice 2017 4:19

    Published on:

  9. Content type: Review

    Poly (ADP-ribose) polymerases (PARPs) are an important family of nucleoproteins highly implicated in DNA damage repair. Among the PARP families, the most studied are PARP1, PARP2 and PARP 3. PARP1 is found to ...

    Authors: Mekonnen Sisay and Dumessa Edessa

    Citation: Gynecologic Oncology Research and Practice 2017 4:18

    Published on:

  10. Content type: Research

    While many of these agents have been compared in prospective clinical trials, the gemcitabine/platinumbased regimens have not been compared in a prospective, randomized clinical trial. While bothgemcitabine/ca...

    Authors: Tran N. Le, Rachel E. Harvey, Christine K. Kim, Jubilee Brown, Robert L. Coleman and Judith A. Smith

    Citation: Gynecologic Oncology Research and Practice 2017 4:16

    Published on:

  11. Content type: Review

    Clear cell carcinoma and endometrioid adenocarcinoma are histologic subtypes of ovarian and uterine cancer that demonstrate unique clinical behavior but share common underlying genomic aberrations and oncogeni...

    Authors: Jill K. Alldredge and Ramez N. Eskander

    Citation: Gynecologic Oncology Research and Practice 2017 4:17

    Published on:

  12. Content type: Research

    Although cervical cancer is preventable, it is still the second leading cause of cancer deaths among women in the world. Further, it is estimated that around 5–10% of hospital admissions are due to drug relate...

    Authors: Amsalu Degu, Peter Njogu, Irene Weru and Peter Karimi

    Citation: Gynecologic Oncology Research and Practice 2017 4:15

    Published on:

  13. Content type: Research

    Preparation in the business of medicine is reported to be poor across a number of specialties. No data exist about such preparation in gynecologic oncology training programs. Our objectives were to evaluate cu...

    Authors: Matthew Schlumbrecht, John Siemon, Guillermo Morales, Marilyn Huang and Brian Slomovitz

    Citation: Gynecologic Oncology Research and Practice 2017 4:14

    Published on:

  14. Content type: Research

    Due to the significant morbidity and mortality associated with placenta percreta, alternative management options are needed. Beginning in 2005, our institution implemented a multidisciplinary strategy to patie...

    Authors: Paula S. Lee, Samantha Kempner, Michael Miller, Jennifer Dominguez, Chad Grotegut, Jessie Ehrisman, Rebecca Previs, Laura J. Havrilesky, Gloria Broadwater, Sarah C. Ellestad and Angeles Alvarez Secord

    Citation: Gynecologic Oncology Research and Practice 2017 4:11

    Published on:

  15. Content type: Research

    To determine the cost-effectiveness of transversus abdominis plane block with liposomal bupivacaine (TAP) compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early e...

    Authors: Brandon-Luke L. Seagle, Emily S. Miller, Anna E. Strohl, Anna Hoekstra and Shohreh Shahabi

    Citation: Gynecologic Oncology Research and Practice 2017 4:12

    Published on:

  16. Content type: Review

    Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacteria...

    Authors: Brett Miles, Howard P. Safran and Bradley J. Monk

    Citation: Gynecologic Oncology Research and Practice 2017 4:10

    Published on:

  17. Content type: Review

    Immune responses to the facultative intracellular bacterium Listeria monocytogenes (Lm) are robust and well characterized. Utilized for decades as a model of host-disease immunology, Lm is well suited for use as ...

    Authors: Brett A. Miles, Bradley J. Monk and Howard P. Safran

    Citation: Gynecologic Oncology Research and Practice 2017 4:9

    Published on:

  18. Content type: Erratum

    Authors: Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, Florencia Djigma, Kafui Akakpo, Ebenezer Aniakwa-Bonsu, Daniel Amoako-Sakyi, Jacques Simpore and Philippe Mayaud

    Citation: Gynecologic Oncology Research and Practice 2017 4:8

    Published on:

    The original article was published in Gynecologic Oncology Research and Practice 2017 4:5

  19. Content type: Review

    Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis ...

    Authors: Bradley J. Monk, Warner K. Huh, Julie Ann Rosenberg and Ira Jacobs

    Citation: Gynecologic Oncology Research and Practice 2017 4:7

    Published on:

  20. Content type: Research

    Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as...

    Authors: Radoslav Chekerov, Philipp Harter, Stefan Fuxius, Lars Christian Hanker, Linn Woelber, Lothar Müller, Peter Klare, Wolfgang Abenhardt, Yoana Nedkova, Isil Yalcinkaya, Georg Heinrich, Harald Sommer, Sven Mahner, Pauline Wimberger, Dominique Koensgen-Mustea, Rolf Richter…

    Citation: Gynecologic Oncology Research and Practice 2017 4:6

    Published on:

  21. Content type: Research

    Modern cervical cancer screening increasingly relies on the use of molecular techniques detecting high-risk oncogenic human papillomavirus (hr-HPV). A major challenge for developing countries like Ghana has be...

    Authors: Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, Florencia Djigma, Kafui Akakpo, Ebenezer Aniakwa-Bonsu, Daniel Amoako-Sakyi, Jacques Simpore and Philippe Mayaud

    Citation: Gynecologic Oncology Research and Practice 2017 4:5

    Published on:

    The Erratum to this article has been published in Gynecologic Oncology Research and Practice 2017 4:8

  22. Content type: Review

    Until recently our knowledge of a genetic contribution to ovarian cancer focused almost exclusively on mutations in the BRCA1/2 genes. However, through germline and tumor sequencing an understanding of the larger...

    Authors: Melissa K. Frey and Bhavana Pothuri

    Citation: Gynecologic Oncology Research and Practice 2017 4:4

    Published on:

  23. Content type: Case Report

    Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 bl...

    Authors: Sarah E. Paraghamian, Teresa C. Longoria and Ramez N. Eskander

    Citation: Gynecologic Oncology Research and Practice 2017 4:3

    Published on:

  24. Content type: Review

    Merkel cell carcinoma is a rare and aggressive neoplasm originating from mechanoreceptor Merkel cells of the stratum basale of the epidermis. Cases affecting the vulva are exceedingly rare, with the currently ...

    Authors: Austin Huy Nguyen, Ahmed I. Tahseen, Adam M. Vaudreuil, Gabriel C. Caponetti and Christopher J. Huerter

    Citation: Gynecologic Oncology Research and Practice 2017 4:2

    Published on:

  25. Content type: Research

    The National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) recommend lymph node sampling (LNS) as a key component in the surgical staging of high-grade endometrial cancer. O...

    Authors: Jonathan R. Foote, Stephanie Gaillard, Gloria Broadwater, Julie A. Sosa, Brittany Davidson, Mohamed A. Adam, Angeles Alvarez Secord, Monica B. Jones, Junzo Chino and Laura J. Havrilesky

    Citation: Gynecologic Oncology Research and Practice 2017 4:1

    Published on:

  26. Content type: Review

    Endometrial carcinoma (EC) is the fourth most common cancer in women in the developed world. Classification of ECs by histomorphologic criteria has limited reproducibility and better tools are needed to distin...

    Authors: A. Talhouk and J. N. McAlpine

    Citation: Gynecologic Oncology Research and Practice 2016 3:14

    Published on:

  27. Content type: Research

    Genetic testing for an inherited susceptibility to cancer is an emerging technology in medical practice. Little information is currently available about physicians’ attitudes towards these tests in developing ...

    Authors: Hanoon P Pokharel, Neville F Hacker and Lesley Andrews

    Citation: Gynecologic Oncology Research and Practice 2016 3:12

    Published on:

  28. Content type: Research

    Chemotherapy plays a role in the treatment of endometrioid endometrial cancer (EEC); however, tumor grade may affect response. Our objective was to evaluate associations between tumor grade and in vitro chemor...

    Authors: Brittany A. Davidson, Jonathan Foote, Stacey L. Brower, Chunqiao Tian, Laura J. Havrilesky and Angeles Alvarez Secord

    Citation: Gynecologic Oncology Research and Practice 2016 3:13

    Published on:

  29. Content type: Meeting report

    The Fifth Annual Advanced Course in Cytoreductive Surgery for Ovarian Cancer and Peritoneal Surface Malignancies was held at and sponsored by the Division of Gynecologic Oncology at the the University of Calif...

    Authors: Krishnansu S. Tewari

    Citation: Gynecologic Oncology Research and Practice 2016 3:10

    Published on:

  30. Content type: Review

    Cervical cancer is the fourth most common cancer among women worldwide, many of who are still within their reproductive lifespan. Advances in screening and treatment have increased the 5-year survival for earl...

    Authors: Karla Willows, Genevieve Lennox and Allan Covens

    Citation: Gynecologic Oncology Research and Practice 2016 3:9

    Published on:

  31. Content type: Research

    Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometria...

    Authors: Michelle Glasgow, Rachel Isaksson Vogel, Jennifer Burgart, Peter Argenta, Kathryn Dusenbery and Melissa A. Geller

    Citation: Gynecologic Oncology Research and Practice 2016 3:6

    Published on:

  32. Content type: Case report

    Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a n...

    Authors: Munetaka Takekuma, Kwong K. Wong and Robert L. Coleman

    Citation: Gynecologic Oncology Research and Practice 2016 3:5

    Published on:

  33. Content type: Research

    After platinum and taxane chemotherapy, with or without bevacizumab, active regimens for advanced or recurrent cervical cancer are lacking. Our objective was to review a single institution experience in treati...

    Authors: Lindsey E. Minion, Dana M. Chase, John H. Farley, Lyndsay J. Willmott and Bradley J. Monk

    Citation: Gynecologic Oncology Research and Practice 2016 3:4

    Published on:

  34. Content type: Review

    Poly(ADP-ribose) polymerase (PARP), which was first described over 50 years ago by Mandel, are a family of protein enzymes involved in DNA damage response and works by recognizing the single-strand DNA break (...

    Authors: Robert S. Meehan and Alice P. Chen

    Citation: Gynecologic Oncology Research and Practice 2016 3:3

    Published on:

  35. Content type: Research

    Many women who develop endometrial cancer (EC) or endometrial hyperplasia with atypia are obese and therefore at high risk of surgical complications. Recently clinical trials have been initiated offering non-s...

    Authors: Andreas Obermair, Donal J. Brennan, Eva Baxter, Jane E. Armes, Val Gebski and Monika Janda

    Citation: Gynecologic Oncology Research and Practice 2016 3:1

    Published on:

  36. Content type: Case report

    Radiation induced Lumbosacral plexophaty (RILP) is a rare but severe complication that has a considerable impact on quality of life. Its occurrence is rare but increasing with improved long-term cancer surviva...

    Authors: Imane Bourhafour, Meriem Benoulaid, Hanane El Kacemi, Sanae El Majjaoui, Tayeb Kebdani and Noureddine Benjaafar

    Citation: Gynecologic Oncology Research and Practice 2015 2:12

    Published on:

  37. Content type: Review

    Endometrial cancer is the only gynecologic malignancy with a rising incidence and mortality. While cure is routinely achieved with surgery alone or in combination with adjuvant pelvic radiotherapy when disease...

    Authors: Teresa C. Longoria and Ramez N. Eskander

    Citation: Gynecologic Oncology Research and Practice 2015 2:11

    Published on:

    The Erratum to this article has been published in Gynecologic Oncology Research and Practice 2016 3:2

  38. Content type: Research

    Early-stage vaginal and vulvar cancer can be cured. But outcomes of patients with metastatic disease are poor. Thus, new therapeutic strategies are urgently required.

    Authors: Siqing Fu, Naiyi Shi, Jennifer Wheler, Aung Naing, Filip Janku, Sarina Piha-Paul, Jing Gong, David Hong, Apostolia Tsimberidou, Ralph Zinner, Vivek Subbiah, Ming-Mo Hou, Pedro Ramirez, Lois Ramondetta, Karen Lu and Funda Meric-Bernstam

    Citation: Gynecologic Oncology Research and Practice 2015 2:10

    Published on:

  39. Content type: Research

    The incidence of molar pregnancy has demonstrated marked geographic and ethnic differences. The reported data in Nepal is inconsistent with minimal published literature. Thus, we designed a study to determine ...

    Authors: Nimisha Agrawal, Reshu Agrawal Sagtani, Shyam Sundar Budhathoki and Hanoon P. Pokharel

    Citation: Gynecologic Oncology Research and Practice 2015 2:9

    Published on:

  40. Content type: Review

    Despite the introduction of screening and, latterly, vaccination programs in the developed world, globally cervical cancer remains a significant health problem. For those diagnosed with advanced or recurrent d...

    Authors: Victor Rodriguez-Freixinos and Helen J. Mackay

    Citation: Gynecologic Oncology Research and Practice 2015 2:8

    Published on:

  41. Content type: Case report

    Cervical cancer (CC) is one of the most widespread gynecological malignancies in women worldwide. Treatment strategies and screening modalities have largely evolved these past years resulting in an improvement...

    Authors: J. Khalil, S. Bellefqih, N. Sahli, M. Afif, H. Elkacemi, S. Elmajjaoui, T. Kebdani and N. Benjaafar

    Citation: Gynecologic Oncology Research and Practice 2015 2:7

    Published on:

  42. Content type: Research

    In Ethiopia, cervical cancer (CC) ranks the 2nd most frequent cancer and the country had 27.19 million women at risk of developing the disease though only 0.6 % women age 18-69 years was screened every 3 years...

    Authors: Netsanet Belete, Yosief Tsige and Habtamu Mellie

    Citation: Gynecologic Oncology Research and Practice 2015 2:6

    Published on:

  43. Content type: Review

    Recently accumulated evidence has strongly indicated that the fallopian tube is the site of origin for the majority of high-grade serous ovarian or peritoneal carcinomas. As a result, recommendations have been...

    Authors: Gillian E. Hanley, Jessica N. McAlpine, Janice S. Kwon and Gillian Mitchell

    Citation: Gynecologic Oncology Research and Practice 2015 2:5

    Published on:

  44. Content type: Case report

    Compared to other subtypes of epithelial ovarian cancer, clear cell carcinoma of the ovary bears an ominous reputation for chemotherapy resistance, increased relapse rate, and diminished survival. Among patien...

    Authors: Michael P. Castro, Bradford P. Whitcomb, Deborah A. Zajchowski and Robert L. Coleman

    Citation: Gynecologic Oncology Research and Practice 2015 2:4

    Published on:

  45. Content type: Research

    Cancer of uterine cervix is the second most common cause of cancer related deaths among women. The aim of this study is to report the experience of Military Hospital Mohamed V in the management of cervical can...

    Authors: Mohammed Elmarjany, Abdelhak Maghous, Rachid Razine, Elamin Marnouche, Khalid Andaloussi, Amine Bazine, Issam Lalya, Noha Zaghba, Khalid Hadadi, Hassan Sifat, Baba Habib, Jaouad Kouach and Hamid Mansouri

    Citation: Gynecologic Oncology Research and Practice 2015 2:2

    Published on:

2017 Journal Metrics

  • Speed
    59 days from submission to first decision
    89 days from submission to acceptance
    14 days from acceptance to publication

    Usage 
    100,314 Downloads
    54 Altmetric Mentions

Advertisement